Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.71 |
| ▸ | HPGD | P15428 | 2/20 | 0.71 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.71 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22691969 | 1.00 | EGFR (0.71) | EGFRHPGDCISD1KDM4ESLC16A3 | |
| SCHEMBL4600832 | 0.90 | EGFR (0.85) | EGFRHPGDCISD1KDM4ESLC16A3 | |
| SCHEMBL10413058 | 0.90 | EGFR (0.85) | EGFRHPGDCISD1KDM4ESLC16A3 | |
| SCHEMBL4600830 | 0.90 | EGFR (0.85) | EGFRHPGDCISD1KDM4ESLC16A3 | |
| SCHEMBL28607522 | 0.86 | EGFR (0.67) | EGFRHPGDCISD1KDM4ESLC16A3 | |
| Alpha-Cyano-4-Hydroxycinnamic Acid SCHEMBL437568 | 0.83 | KDM4E (1.00) | EGFRHPGDCISD1KDM4ESLC16A3 | |
| SCHEMBL8749181 | 0.83 | EGFR (1.00) | EGFRHPGDCISD1KDM4ESLC16A3 | |
| Alpha-Cyano-4-Hydroxycinnamic Acid SCHEMBL26825 | 0.83 | KDM4E (1.00) | EGFRHPGDCISD1KDM4ESLC16A3 | |
| Alpha-Cyano-4-Hydroxycinnamic Acid SCHEMBL28529867 | 0.83 | KDM4E (1.00) | EGFRHPGDCISD1KDM4ESLC16A3 | |
| Alpha-Cyano-4-Hydroxycinnamic Acid SCHEMBL26826 | 0.83 | KDM4E (1.00) | EGFRHPGDCISD1KDM4ESLC16A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12607636-B2 | Carbene mass tagging | NORTHEASTERN UNIVERSITY (US) | 2026-04-21 | — | — | US | disclosed |
| US-20220244265-A1 | CARBENE MASS TAGGING | NORTHEASTERN UNIVERSITY | 2022-08-04 | — | — | US | disclosed |
| WO-2020237132-A1 | CARBENE MASS TAGGING | NORTHEASTERN UNIVERSITY (US) | 2020-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12607636-B2 | Carbene mass tagging | SLCO1B3, SLCO2B1, SLCO2A1 | EGFR 3412/4885HPGD 3977/4885CISD1 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.